122
Views
18
CrossRef citations to date
0
Altmetric
Review

Peptide nucleic acids as antibacterial agents via the antisense principle

Pages 331-341 | Published online: 24 Feb 2005

Bibliography

  • MYERS KJ, DEAN NM: Sensible use of antisense: how to use oligonucleotides as research tools. Trends Pharmacol. Sci. (2000) 21:19–23.
  • AGRAWAL S, KANDIMALLA ER: Antisense therapeutics: is it as simple as complementary base recognition? Mol. Med. Today (2000) 6:72–81.
  • MARCUSSON EG, YACYSHYN BR, SHANAHAN WR, JR., DEAN NM: Preclinical and clinical pharmacology of antisense oligonucleotides. Mol. Biotechnol. (1999) 1 2:1–11.
  • JULIANO RL, ALAHARI S, Y00 H, KOLE R, CHO M: Antisense pharmacodynamics: critical issues in the transport and delivery of antisense oligonucleotides. Pharm. Res. (1999) 16:494–502.
  • KHATSENKO 0, MORGAN R, TRUONG L et al.: Absorp-tion of antisense oligonucleotides in rat intestine: effect of chemistry and length. Antisense Nucleic Acid Drug Dev. (2000) 10:35–44
  • HUDZIAK RM, SUMMERTON J, WELLER DD, IVERSON PL: Antiproliferative effects of steric blocking phosphoro-diamidate morpholino antisense agents directed against c-myc. Antisense Nucleic Acid Drug Dev. (2000) 1 0:163–176.
  • RAPAPORT E, LEVINA A, METELEV V, ZAMECNIK PC: Antimycobacterial activities of antisense oligode-oxynucleotide phosphorothioates in drug-resistant strains. Proc. Natl. Acad. Sci. USA (1996) 93:709–713.
  • HARTH G, ZAMECNIK PC, TANG JY, TABATADZE D, HORWITZ MA: Treatment of Mycobacterium tubercu-losis with antisense oligonucleotides to glutamine synthetase mRNA inhibits glutamine synthetase activity, formation of the poly-L-glutamate/glutamine cell wall structure and bacterial replication. Proc. Natl. Acad. Sci. USA (2000) 97:418–423.
  • •Building on the results of reference 7, this paper demonstrates the potential of phosphorothioates for antibacterial drug development. NIELSEN PE, EGHOLM M, BERG RH, BUCHARDT 0: Sequence-selective recognition of DNA by strand displacement with a thymine-substituted polyamide. Science (1991) 254:1497–1500.
  • NIELSEN PE, EGHOLM M, BERG RH, BUCHARD 0: Peptidenucleic acids (PNA): oligonucleotide analogs with a polyamide backbone. In: Antisense Research and Applica-tions. Crooke ST, Lebleu B (Eds.), CRC Press, Boca Raton, USA (1993):364–373.
  • NIELSEN PE, EGHOLM M, BUCHARDT 0: Evidence for(PNA)2/DNA triplex structure upon binding of PNA to dsDNA by strand displacement. J. Mol. Recognit. (1994) 7:165–170.
  • JENSEN KK, ORUM H, NIELSEN PE, NORDEN B: Kinetics for hybridization of peptide nucleic acids (PNA) with DNA and RNA studied with the BlAcore technique. Biochemistry (1997) 36:5072–5077.
  • EGHOLM M, BUCHARDT 0, CHRISTENSEN L et al.: PNA hybridizes to complementary oligonucleotides obeying the Watson-Crick hydrogen-bonding rules. Nature (1993) 365:566–568.
  • DEMIDOV V, POTAMAN VN, FRANK-KAMENETSKII MD etal.: Stability of peptide nucleic acids in human serum and cellular extracts. Biochem. Pharmacol. (1994) 48:1310–1313.
  • NIELSEN PE: PNA targeting of double stranded DNA. Methods Enzymol. (In Press).
  • HANVEY JC, PEFFER NJ, BISI JE et al.: Antisense and antigen properties of peptide nucleic acids. Science (1992) 258:1481–1485.
  • KNUDSEN H, NIELSEN PE: Antisense properties of duplex- and triplex-forming PNAs. Nucleic Acids Res. (1996) 24:494–500.
  • MOLOGNI L, LECOUTRE P, NIELSEN PE, GAMBACORTI-PASSERINI C: Additive antisense effects of different PNAs on the in vitro tr an slation of the PML/RAR alpha. gene. Nucleic Acids Res. (1998) 26:1934–1938.
  • BONHAM MA, BROWN SC, BOYD AL et al.: An assess-ment of the antisense properties of RNase H-competent and steric-blocking oligomers. Nucleic Acids Res. (1995) 23:1197–1203.
  • WITTUNG P, KAJANUS J, EDWARDS K, NIELSEN P, NORDEN B, MALMSTROEM BG: Phospholipid membrane permeability of peptide nucleic acid. FEBS Lett. (1995) 365:27–29.
  • POOGA M, SOOMETS U, HALLBRINK M et al.: Cell penetrating PNA constructs regulate galanin receptor levels and modify pain transmission in vivo. Nature Biotechnol. (1998) 16:857–861.
  • ALDRIAN-HERRADA G, DESARMENIEN MG, ORCEL H et al.: A peptide nucleic acid (PNA) is more rapidly internalized in cultured neurons when coupled to a retro-inverso delivery peptide. The antisense activity depresses the target mRNA and protein in magnocel-lular oxytocin neurons. Nucleic Acids Res. (2000) 26:4910–4916.
  • CUTRONA G, CARPANETO EM, ULIVI M et al.: Effects inlive cells of a c-myc anti-gene PNA linked to a nuclear localization signal. Nature Biotechnol. (2000)18:300–303.
  • •The small, cationic NLS peptide is introduced as a cellular delivery vehicle for PNA.
  • HAMILTON SE, SIMMONS CG, KATHIRIYA IS, COREY DR: Cellular delivery of peptide nucleic acids and inhibi-tion of human telomerase. Chem. Biol. (1999) 6:343–351.
  • •In this paper, it is demonstrated that PNA oligomers can be delivered effectively to eukaryotic cells via cationic liposomes provided they are complexed with a partially complementary oligonucleotide.
  • LJUNGSTROM T, KNUDSEN H, NIELSEN PE: Cellularuptake of adamantyl conjugated peptide nucleic acids. Bioconjugate Chem. (1999) 1 0 :965–972.
  • SCARFI S, GIOVINE M, GASPARINI A et al.: Modifiedpeptide nucleic acids are internalized in mouse macrophages RAW 264.7 and inhibit inducible nitric oxide syntase. FEBS Lett. (1999) 451:264–268.
  • HERBERT BS, PITTS AE, BAKER SI et al.: Inhibition ofhuman telomerase in immortal human cells leads to progressive telomere shortening and cell death. Proc. Natl. Acad. Sci. USA (1999) 96:14276–14281.
  • •Phenotypic effects of antitelomerase PNAs in terms of cell survival are demonstrated, and evidence is presented that this effect is caused by telomere shorting due to inhibition of telomerase activity. Thus development of PNA anticancer drugs may be envisaged using this principle.
  • SHAMMAS MA, SIMMONS CG, COREY DR, REIS RJS: Telomerase inhibition by peptide nucleic acids reverses immortality' of transformed human cells. Oncogene (1999) 18:6191–6200.
  • VILLA R, FOLINI M, LUALDI S, VERONESE S, DAIDONEMG, ZAFFARONI N: Inhibition of telomerase activity by a cell-penetrating peptide nucleic acid construct in human melanoma cells. FEBS Lett. (2000) 473:241–248.
  • CHINNERY PF, TAYLOR RW, DIEKERT K, LILL R,TURNBULL DM, LIGHTOWLERS RN: Peptide nucleic acid delivery to human mitochondria. Gene Ther. (1999) 6 :1919–1928.
  • BOFFA LC, SCARFI S, MARIANI MR et al.: Dihydrotestos-terone as a selective cellular/nuclear localization vector for anti-gene peptide nucleic acid in prostatic carcinoma cells. Cancer Res. (2000) 60:2258–2262.
  • SEI S, YANG QE, O'NEILL D, YOSHIMURA K, MITSUYA H: Identification of a key target sequence to block human immunodeficiency virus Type 1 replication within the gag-p ol transframe domain. J. Virology (2000) 74:4621–4633.
  • •For the first time antisense PNAs are found to inhibit HIV reproduction in cells in culture.
  • GRIFFITH MC, RISEN LM, GREIG MJ et al.: Single and bis peptide nucleic acids as triplexing agents: binding and stoichiometry. J. Am. Chem. Soc. (1995) 117:831–832.
  • KOSAGANOV YUN, STETSENKKO DA, LUBYAKO EN, KVITKO NP, LAZURKIN YUS, NIELSEN PE: Effect of temperature and ionic strength on the dissociation kinetics and life time of PNA-DNA triplexes. Biochem-istry (2000) 39:11742–11747.
  • NIELSEN PE, EGHOLM M, BERG RH, BUCHARDT 0: Sequence specific inhibition of DNA restriction enzyme cleavage by PNA. Nucleic Acids Res. (1993) 21:197–200.
  • NIELSEN PE, EGHOLM M, BUCHARDT 0: Sequence- specific transcription arrest by peptide nucleic acid bound to the DNA template strand. Gene (1994) 149:139–145.
  • VICKERS TA, GRIFFIETH MC, RAMASAMY K, RISEN LM, FREIER SM: Inhibition of NF-KB specific transcriptional activation by PNA strand invasion. Nucleic Acids Res. (1995) 23:3003–3008.
  • BENTIN T, NIELSEN PE: Enhanced peptide nucleic acid binding to supercoiled DNA: possible implications for DNA 'breathing' dynamics. Biochemistry (1996) 35:8863–8869.
  • LARSEN HJ, NIELSEN PE: Transcription-mediated binding of peptide nucleic acid (PNA) to double-stranded DNA: sequence-specific suicide transcrip-tion. Nucleic Acids Res. (1996) 24:458–463.
  • KUHN H, DEMIDOV VV, FRANK-KAMENETSKII MD, NIELSEN PE: Kinetic sequence discrimination of cationic bis-PNAs upon targeting of double-stranded DNA. Nucleic Acids Res. (1998) 26:582–587.
  • ZHANG X, ISHIHARA T, COREY DR: Strand invation by mixed base PNAs and a PNA-peptide chimera. Nucleic Acids Res. (2000) 28:3332–3338.
  • FARUQI AF, EGHOLM M, GLAZER PM: Peptide nucleic acid-targeted mutagenesis of a chromosomal gene in mouse cells. Proc. Natl. Acad. Sci. USA (1998) 95:1398–1403.
  • PRASEUTH D, GRIGORIEV M, GUIEYSSE AL et al.: Peptide nucleic acids directed to the promoter of the alpha-chain of the interleukin-2 receptor. Biochim. Biophys. Acta (1996) 1309:226–238.
  • NIELSEN PE, CHRISTENSEN L: Strand displacement binding of a duplex-forming homopurine PNA to a homopyrimidine duplex DNA target. J. Am. Chem. Soc. (1996) 118:2287–2288.
  • LOHSE J, DAHL 0, NIELSEN PE: Double duplex invasion by peptide nucleic acid: a general principle for sequence-specific targeting of double-stranded DNA. Proc. Nail. Acad. Sci. USA (1999) 96:11804–11808.
  • KOPPELHUS U, ZACHAR V, NIELSEN PE, LIU X, EUGEN-OLSEN J, EBBESEN P: Efficient in vitro inhibition of HEV-1 gag reverse transcription by peptide nucleic acid (PNA) at minimal ratios of PNA/RNA. Nucleic Acids Res. (1997) 25:2167–2173.
  • LEE R, KAUSHIK N, MODAK MJ, VINAYAK R, PANDEY VN: Polyamide nucleic acid targeted to the primer binding site of the HIV-1 RNA genome blocks in vitro HEV-1 reverse transcription. Biochemistry (1998) 37:900–910.
  • BOULME F, FREUND F, MOREAUL S et al.: Modified (PNA, 2'-0-methyl and phosphoramidate) anti-TAR antisense oligonucleotides as strong and specific inhibitors of in vitro HIV-1 reverse transcription. Nucleic Acids Res. (1998) 26:5492–5500.
  • GOOD L, NIELSEN PE: Inhibition of translation andbacterial growth by peptide nucleic acid targeted to ribosomal RNA. Proc. Natl. Acad. Sci. USA (1998) 95:2073–2076.
  • GOOD L, NIELSEN PE: Antisense inhibition of gene expression in bacteria by PNA targeted to mRNA. Nature Biotechnol (1998) 16:355–358.
  • HANCOCK RE: Peptide antibiotics. Lancet (1997) 349:418–422.
  • VAARA M, PORRO M: Group of peptides that act synergistically with hydrophobic antibiotics against Gram-negative enteric bacteria. Antimicrob. Agents Chemother. (1996) 40:1801–1805.
  • GOOD L, SANDBERG R, LARSSON 0, NIELSEN PE: Antisense PNA effects in Escherichia coli are limited by the outher-membrane LPS layer. Microbiology (2000) 146:2665–2670.
  • •It is demonstrated that the nonapeptide from polymyxin B synergistically enhances PNA antisense effects on E. coli.
  • SCHOU C, HANSEN HF, NIELSEN PE et al: Antibiotic effects of PNA (peptide nucleic acid) antisense compounds against multiresistant Echerichia coli. (Poster presented at ICAAC (2000) Toronto, Canada).
  • •This is the first report showing that effective PNA-based antibacterials can be constructed, and that these are active in vivo on an E. coli infection in a peritonitis/sepsis mouse model.
  • TYLER BM, MCCORMICK DJ, HOSHALL CV et al.: Specific gene blockade shows that peptide nucleic acids readily enter neuronal cells in vivo. FEBS Lett. (2000) 421:280–284.
  • FRASER GL, HOLMGREN J, CLARKE PBS, WAHLESTEDT C: Antisense inhibition of .5-opioid receptor gene function in vivo by peptide nucleic acids. Mal Pharmacol. (2000) 57:725–731.
  • •This paper reports antisense compatible effects of PNA oligomers injected into the brain of rats.
  • WANG G, XU X, PACE B, DEAN DA: Peptide nucleic acid (PNA) binding-mediated induction of human gamma-globin gene expression. Nucleic Acids Res. (1999) 27 (13):2806–2813

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.